JPWO2021093764A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021093764A5 JPWO2021093764A5 JP2022526767A JP2022526767A JPWO2021093764A5 JP WO2021093764 A5 JPWO2021093764 A5 JP WO2021093764A5 JP 2022526767 A JP2022526767 A JP 2022526767A JP 2022526767 A JP2022526767 A JP 2022526767A JP WO2021093764 A5 JPWO2021093764 A5 JP WO2021093764A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 272
- 239000000126 substance Substances 0.000 claims description 57
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/117155 | 2019-11-11 | ||
| CN2019117155 | 2019-11-11 | ||
| PCT/CN2020/128083 WO2021093764A1 (en) | 2019-11-11 | 2020-11-11 | Pharmaceutical combination and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500385A JP2023500385A (ja) | 2023-01-05 |
| JP2023500385A5 JP2023500385A5 (https=) | 2023-11-20 |
| JPWO2021093764A5 true JPWO2021093764A5 (https=) | 2023-11-20 |
Family
ID=75911807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526767A Pending JP2023500385A (ja) | 2019-11-11 | 2020-11-11 | 医薬組合せ物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220387417A1 (https=) |
| EP (1) | EP4031179A4 (https=) |
| JP (1) | JP2023500385A (https=) |
| KR (1) | KR20220103961A (https=) |
| CN (1) | CN114901309A (https=) |
| AU (1) | AU2020383580A1 (https=) |
| BR (1) | BR112022009042A2 (https=) |
| CA (1) | CA3160526A1 (https=) |
| IL (1) | IL292646A (https=) |
| MX (1) | MX2022005034A (https=) |
| WO (1) | WO2021093764A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4450616A3 (en) * | 2016-09-21 | 2025-01-01 | Cstone Pharmaceuticals | The novel monoclonal antibodies to programmed death 1 (pd-1) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102675282B (zh) * | 2011-03-15 | 2014-12-24 | 广东东阳光药业有限公司 | 取代的喹啉化合物及其使用方法和用途 |
| KR20220019839A (ko) * | 2013-10-08 | 2022-02-17 | 다이이찌 산쿄 가부시키가이샤 | 항 fgfr2 항체와 타제의 조합 |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| KR102662228B1 (ko) * | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CN106432501B (zh) * | 2015-08-06 | 2021-07-30 | 基石药业 | 新型抗pd-l1抗体 |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN108778330A (zh) * | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| EP4450616A3 (en) * | 2016-09-21 | 2025-01-01 | Cstone Pharmaceuticals | The novel monoclonal antibodies to programmed death 1 (pd-1) |
| CN107840887B (zh) * | 2016-09-21 | 2022-03-25 | 基石药业（苏州）有限公司 | 一种新的pd-1单克隆抗体 |
| KR102655301B1 (ko) * | 2017-04-06 | 2024-04-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
| CN110536694A (zh) * | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | 用于治疗肺部炎症的组合物和方法 |
| CN109988112A (zh) * | 2017-12-29 | 2019-07-09 | 四川科伦药物研究院有限公司 | 仑伐替尼甲磺酸盐的晶型及其制备方法 |
| CN108379591B (zh) * | 2018-04-03 | 2022-03-29 | 深圳大学 | 免疫激动剂靶向化合物的合成及其应用 |
| CN109731019B (zh) * | 2019-03-07 | 2021-07-16 | 康赋葆(深圳)生物医药科技有限公司 | 一种具有化疗增效作用的组合物，包括组成、制备及应用 |
| CN109867626A (zh) * | 2019-04-18 | 2019-06-11 | 安礼特（上海）医药科技有限公司 | 一种甲磺酸仑伐替尼多晶型物及其制备方法 |
-
2020
- 2020-11-11 EP EP20888069.0A patent/EP4031179A4/en not_active Withdrawn
- 2020-11-11 WO PCT/CN2020/128083 patent/WO2021093764A1/en not_active Ceased
- 2020-11-11 MX MX2022005034A patent/MX2022005034A/es unknown
- 2020-11-11 US US17/776,179 patent/US20220387417A1/en active Pending
- 2020-11-11 AU AU2020383580A patent/AU2020383580A1/en active Pending
- 2020-11-11 KR KR1020227017523A patent/KR20220103961A/ko not_active Ceased
- 2020-11-11 CA CA3160526A patent/CA3160526A1/en active Pending
- 2020-11-11 JP JP2022526767A patent/JP2023500385A/ja active Pending
- 2020-11-11 CN CN202080078664.3A patent/CN114901309A/zh active Pending
- 2020-11-11 BR BR112022009042A patent/BR112022009042A2/pt unknown
-
2022
- 2022-05-01 IL IL292646A patent/IL292646A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7401126B2 (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| US20220332821A1 (en) | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen | |
| JP2020528750A5 (https=) | ||
| JP2019532056A5 (https=) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2017514795A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2017535246A5 (https=) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2020522280A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JPWO2021139777A5 (https=) | ||
| CN112074538A (zh) | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 | |
| JP2020505075A5 (https=) | ||
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2019243159A5 (https=) | ||
| JP2020523414A (ja) | Ｌｇｒ５に結合する抗体薬物複合体 | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| WO2018065938A1 (en) | Dosing regimen of avelumab for the treatment of cancer | |
| WO2025082449A1 (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| JPWO2021093764A5 (https=) |